Literature DB >> 19194340

Immunosuppression and melanocyte proliferation.

Edoardo Zattra1, Anna Belloni Fortina, Matteo Bordignon, Stefano Piaserico, Mauro Alaibac.   

Abstract

Melanocytes are pigmented cells derived from the neural crest; their proliferation is restrained by immune system. The eruption of nevi after an immunosuppressive condition is a peculiar phenomenon indicating that the immune system may play a major role in limiting proliferation of melanocytes. In this review, we analyze the role of immunosuppressive regimens on melanocyte proliferation. In particular, we discuss the eruptive nevi phenomenon, which is determined by the inability of the immune system to inhibit melanocyte proliferation. These clinical observations indicate that the immune system has a pivotal role in restraining melanocyte proliferation. However, although the role of the immune system in the development of nonmelanoma skin cancer has been shown clearly in several studies involving organ transplant patients, the role of immunosuppression in melanoma genesis has not yet been established. Further investigations are required to establish the real immunogenicity of melanoma, particularly in the light of the dichotomy between the eruptive nevi phenomenon in immunosuppressed patients and the low incidence of melanoma in transplanted patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194340     DOI: 10.1097/CMR.0b013e328322fc20

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  16 in total

1.  A germline variant in the interferon regulatory factor 4 gene as a novel skin cancer risk locus.

Authors:  Jiali Han; Abrar A Qureshi; Hongmei Nan; Jiangwen Zhang; Yiqing Song; Qun Guo; David J Hunter
Journal:  Cancer Res       Date:  2011-01-26       Impact factor: 12.701

2.  Surgical suturing-induced melanocytic nevi. A new type of eruptive melanocytic nevi?

Authors:  Alexander C Katoulis; Dimitrios Sgouros; Giuseppe Argenziano; Efstathios Rallis; Ioannis Panayiotides; Dimitrios Rigopoulos
Journal:  J Dermatol Case Rep       Date:  2016-11-30

3.  Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study.

Authors:  Jessica Bogach; Frances C Wright; Janice Austin; Stephanie Y Cheng; Christina Diong; Rinku Sutradhar; Nancy N Baxter; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2020-10-16       Impact factor: 5.344

4.  Toll-like receptors and cutaneous melanoma.

Authors:  Ilaria Coati; Serena Miotto; Irene Zanetti; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

Review 5.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

6.  [Eruptive melanocytic nevi during azathioprine therapy in myasthenia gravis].

Authors:  S A Braun; D Helbig; J Frank; S Hanneken
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

7.  Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.

Authors:  P Dillon; N Thomas; N Sharpless; F Collichio
Journal:  Med Oncol       Date:  2009-11-05       Impact factor: 3.064

8.  Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy.

Authors:  Marina T van Leeuwen; Claire M Vajdic; Melanie G Middleton; Ann M McDonald; Matthew Law; John M Kaldor; Andrew E Grulich
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

9.  Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.

Authors:  Alberto Meneguzzo; Annalisa Lazzarotto; Mauro Alaibac
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

10.  Aberrant Induction of a Mesenchymal/Stem Cell Program Engages Senescence in Normal Mammary Epithelial Cells.

Authors:  Benjamin L Bryson; Ilaria Tamagno; Sarah E Taylor; Neetha Parameswaran; Noah M Chernosky; Nikhila Balasubramaniam; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2020-12-22       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.